Caxton Associates LLP Makes New Investment in Humana Inc. $HUM

Caxton Associates LLP purchased a new stake in Humana Inc. (NYSE:HUM) during the 1st quarter, HoldingsChannel reports. The firm purchased 5,646 shares of the insurance provider’s stock, valued at approximately $979,000.

Several other hedge funds and other institutional investors have also modified their holdings of HUM. Revolve Wealth Partners LLC bought a new position in Humana during the fourth quarter valued at about $202,000. Woodline Partners LP raised its stake in Humana by 460.0% during the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after acquiring an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Humana by 53.7% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after purchasing an additional 452 shares during the last quarter. Cresset Asset Management LLC raised its stake in shares of Humana by 10.3% in the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after acquiring an additional 222 shares during the last quarter. Finally, WINTON GROUP Ltd raised its position in Humana by 58.5% in the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after purchasing an additional 879 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HUM shares. Leerink Partners boosted their target price on shares of Humana from $185.00 to $255.00 and gave the stock a “market perform” rating in a research note on Thursday, April 30th. Oppenheimer raised shares of Humana from an “outperform” rating to an “outperform” rating in a research note on Wednesday, May 20th. Wells Fargo & Company raised shares of Humana from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $227.00 to $502.00 in a report on Monday, July 13th. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 29th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Humana in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $327.17.

Humana Stock Performance

Shares of NYSE:HUM opened at $388.56 on Monday. The stock has a market capitalization of $46.65 billion, a P/E ratio of 41.56, a P/E/G ratio of 2.12 and a beta of 0.71. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $428.88. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $364.10 and a two-hundred day moving average price of $264.93.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The company had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company’s revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the company posted $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts predict that Humana Inc. will post 9.46 earnings per share for the current year.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.